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1001-9 Effect of Free Fatty Acid Inhibition on Left Ventricular 
Function in Diabetic Patients With Coronary Artery 
Disease
Giuseppe M. Rosano, Giuseppe Mercuro, Cristiana Vitale, Barbara Sposato, Massimo 
Fini, San Raffaele Roma, Roma, Italy, University of Cagliari, Cagliari, Italy
In diabetic patients with coronary artery disease free fatty acid blockade with trimetazi-
dine improves myocardial glucose utilization. Aim of the present study was to evaluate
whether the metabolic effect of Trimetazidine on left ventricular function in diabetic
patients with coronary artery disease. We evaluated the effect of chronic administration
of Trimetazidine on left ventricular dimensions and systolic function in 32 patients y (24
males and 8 females, mean (SE) age = 67±6 years) with NIDDM and ischemic cardiomy-
opathy.
Patients were randomized to receive on top of standard therapy either Trimetazidine (20
mg, tds) or Placebo (tds) and were evaluated at baseline and after 6 months.
Demographic data were comparable between the two groups with respect to sex, age,
distribution of CAD, and glicated haemoglobin levels. In the Placebo group, baseline
LVEDD increased from 62.4+1.7 to 63+2.1 mm, while in the Trimetazidine group
decreased from 63.2+2.1 to 58+1.6 mm (p=0.01 compared to baseline). Similarly LVESD
increased from 53+1.3 to 54.2+0.9 mm in the Placebo group and decreased from
52.1+1.5 to 46+1 mm in the Trimetazidine group, respectively (NS).
Compared to baseline, LVEF increased by 5.4±0.5% (p<0.05) in the TMZ group while
remained unchanged in the Placebo group –2.4±1.1% (NS), p<0.01 between groups.
In conclusion, in diabetic patients with ischemic heart disease TMZ added to standard
medical therapy has beneficial effect on LV volumes and on LVEF compared to placebo.
This effect may be related to the effect of TMZ upon cardiac glucose utilization.
Noon
1001-10 Testosterone Replacement Confers a Favourable 
Cytokine Profile in Men With Low Serum Testosterone 
and Coronary Disease
Chris J. Malkin, Peter J. Pugh, Katherine E. Kerry, Richard D. Jones, Dheeraj Kapoor, 
Hugh T. Jones, Kevin S. Channer, Royal Hallamshire Hospital, Sheffield, United 
Kingdom, The University of Sheffield, Sheffield, United Kingdom
Background Men with atherosclerotic coronary disease have lower serum testosterone
(T) levels than men with normal angiograms. T has immune-modulating properties and
replacement therapy inhibits atherogenesis in castrated, male, cholesterol-fed animals.
In-vitro evidence suggests that T suppresses pro-inflammatory cytokines such as tumour
necrosis factor (TNF α) and potentiates the expression of anti-inflammatory cytokines
such as interleukin (IL)-10, these effects may mediate the atheroprotective effect
observed in animals. The effect of T replacement therapy on inflammatory cytokines in
men with coronary disease is explored for the first time in this study.
Methods This was a randomised placebo controlled crossover study of 1 month T
replacement (Sustanon 100) versus placebo in 20 men (age 61 ± 9years) with symptom-
atic androgen deficiency (total T 6.7 ± 2.3 nmol/L (normal range >8.3nmol/L)) and angio-
graphic proven coronary disease (>70% stenosis of > 1 epicardial coronary artery).
Serum cytokines (TNFα, IL-1β and IL-10), cholesterol profiles (total cholesterol, low den-
sity lipoprotein, high density lipoprotein, triglycerides) and hormones (total T and bio-
available T) were recorded at baseline and after treatment from the T and placebo phase.
Results are displayed as mean ± SD. Delta analysis was used to test significance.
Results Compared to placebo, T reduced both TNFα (-4.1 ± 9.1 v 1.5 ± 5.9 pg/ml,
p=0.007) and IL-1β (-0.17 ± 0.3 v 0.2 ± 0.6 pg/ml, p=0.04). An increase in IL-10
approached significance (0.32 ± 2 v –0.87 ± 3.2 pg/ml, p=0.08). There was a trend to
reduction in total cholesterol with T (-0.26 ± 0.5 v –0.005 ± 0.5mmol/L, p=0.1).
Conclusions Testosterone replacement in this cohort shifts the cytokine balance to a
state of reduced inflammation, this may have positive effects on atherosclerotic plaque
biology. Since the prevalence of hypogonadism in men with coronary disease is high
(23%) and the risk of vascular complications and mortality is in part determined by
inflammation. Testosterone may offer prognostic benefit to a large proportion of men with
overt coronary disease.
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1001-11 Lower Doses of Hormone Replacement Therapy Did Not 
Increase hsC-Reactive Protein or F1+2 Levels but 
Improved Flow-Mediated Dilation in Postmenopausal 
Women: A Randomized, Double-Blind, Crossover Study
Kwang K. Koh, Jeong Y. Ahn, Seung H. Han, Mi-Seung Shin, Tae H. Ahn, Eak K. Shin, 
Gachon Medical School, Incheon, South Korea
Objective: The effects of hormone replacement therapy (HRT) can affect many aspects
relevant to cardiovascular disease including vasomotor function, inflammation, and
hemostasis. Recent studies have demonstrated that current doses of HRT exert a mix-
ture of both protective and adverse effects. In the current study, we compared the effects
of lower doses of HRT (L-HRT) and conventional doses of HRT (C-HRT) on a variety of
relevant cardiovascular parameters.
Methods and Results: This randomized, double-blind, crossover study included fifty-
seven women who received micronized progesterone 100 mg with either conjugated
equine estrogen 0.625 mg (C-HRT) or 0.3 mg (L-HRT) daily for 2 months. L-HRT showed
comparable effects to C-HRT on HDL cholesterol and triglyceride levels, but not on LDL
cholesterol levels. C-HRT and L-HRT significantly improved the percent flow-mediated
dilator response to hyperemia from baseline values (both p<0.001) by a similar degree
(p=0.719). C-HRT significantly increased high sensitivity CRP (hsCRP) levels from base-
line values (p<0.001), however, L-HRT did not significantly change hsCRP (p=0.874). C-
HRT and L-HRT significantly decreased antithrombin III from baseline values (p<0.001
and p=0.042, respectively). C-HRT significantly increased prothrombin fragment 1+2
(F1+2) from baseline values (p<0.001), however, L-HRT did not significantly change
F1+2 (p=0.558). Of interest, the effects of C-HRT and L-HRT on hsCRP, antithrombin III,
and F1+2 were significantly different (all p<0.001). C-HRT and L-HRT significantly
reduced plasma PAI-1 antigen levels from baseline values (p=0.002 and p=0.038,
respectively) to a similar degree (p=0.184). *=P<0.05;**=P<0.01;***=P<0.001 vs. Base-
line. Data= mean±SEM or median (25%-75%).
Conclusions: Compared with C-HRT, L-HRT has comparable effects on lipoproteins,
flow-mediated dilation, and PAI-1 antigen levels. However, L-HRT did not increase
hsCRP or F1+2 levels and it decreased antithrombin III less than C-HRT.
Base-1 C-HRT Base-2 L-HRT
hsCRP (mg/dl) 0.08 (0.04-0.17) 0.15 (0.06-0.34)*** 0.08 (0.05-0.25)
0.08 (0.05-0.18)
F1+2 (nmol/l) 1.57 (1.36-1.92) 2.13 (1.51-4.13)*** 1.55 (1.28-2.00)
1.66 (1.36-2.05)
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1001-12 Prevention of Flight-Related Thrombosis With Low-
Molecular Weight Heparin
Belcaro Giovanni, Maria Rosaria Cesarone, Andrew N. Nicolaides, George Geroulakos, 
Edmondo Ippolito, Michele Georgiev, Andrea Di Renzo, Mark Dougall, Morio Ashai, 
Steve Kakkos, The European Venous Forum, Lonflit Consortium and Chieti University, 
London, United Kingdom
The LONFLIT studies established that in high-risk subjects after long (> 10 hours) flights,
the incidence of deep venous thrombosis (DVT) is on average 3.6%. This study had eval-
uated prevention in high-risk subjects with low-molecular weight heparin (LMWH). Of 776
subjects contacted for the study, 458 were included and randomized, into three groups:
1) control group (no prophylaxis); 2) aspirin treatment group (0.4 g of oral, soluble aspirin;
one dose daily for 3 days, starting 12 hours before the beginning of the flight); 3) LMWH
group (4000 UI, dose of enoxaparine, between 2 and 3 hours before flights). Subjects
with potential problems due to prophylaxis with aspirin or LMWH were excluded. A total
of 422 subjects completed the study (dropouts were due to low compliance or travel ).
RESULTS. Age, sex and risk distribution were comparable in the groups. Mean age was
52 (range, 27-78; SD, 12; 63% males). Of the 142 controls (8) 5.6% had thrombotic event
(6 DVTs with two superficial thromboses). In the LMWH group (141 subjects), there were
no DVTs. In the aspirin group (139 subjects) there were 6 events (4.3%) with 4 DVTs.
DVT was asymptomatic in 68% of subjects and 93% of DVTs were observed in subjects
sitting in non-aisle seats. Mild gastrointestinal symptoms were reported in 11% of
patients taking aspirin. In conclusion one fixed dose of LMWH is an important option to
consider in high-risk subjects during long-haul flights.
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1001-13 Gender Bias Against Women: Men Receive Prophylaxis 
More Often to Prevent Deep Venous Thrombosis
Nils Kucher, David McKenzie, Rene Quiroz, Samy S. Mir, Ruth B. Morrison, Victor F. 
Tapson, Samuel Z. Goldhaber, for the DVT FREE Steering Committee, Brigham and 
Women's Hospital, Harvard Medical School, Boston, MA
We investigated gender differences in the prevention of acute deep venous thrombosis
(DVT). We used the database of DVT FREE, a prospective 183-center US registry of
5,451 consecutive patients (46.9% men, 53.1% women) with ultrasound-confirmed DVT.
Detailed information about DVT prophylaxis and medical comorbidities prior to the onset
of the acute DVT was available for 4,652 patients. Men more often than women (33.9%
vs. 29.1%; OR 1.22, 95% CI 1.08-1.38; p = 0.001) received mechanical or pharmaceuti-
cal prophylaxis 30 days prior to the onset of acute DVT. Multivariate adjustment for base-
line characteristics and DVT risk factors did not change this finding (Figure). Men were
20% more likely to receive prophylaxis (adjusted OR 1.20, 95% CI 1.03-1.41; p = 0.021).
Among 2,454 patients hospitalized at the time of DVT diagnosis, 53.5% of women and
46.5% of men had not received prophylaxis or treatment prior to the acute DVT (p =
0.042). When DVT prophylaxis was administered, the type of prophylaxis (66.9% vs.
66.3% pharmacological prophylaxis, 23.8% vs. 23.2% pneumatic compression devices,
16.7% vs. 16.4% vascular compression stockings) was similar between men and women.
Our most disturbing and provocative finding was identification of gender bias against
women: failure to administer DVT prophylaxis to high-risk women more than men who
subsequently developed acute DVT within 30 days. Future efforts should focus on
improved implementation of DVT prophylaxis guidelines among patients at high risk,
especially women.
